Zacks Research Analysts Boost Earnings Estimates for Agios P

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities researchers at Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, May 20th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.59) per share for […]

Related Keywords

Canada , China , United States , James William Burns , Jacqualyna Fouse , Zurcher Kantonalbank Zurich Cantonalbank , Quest Partners , Cantor Fitzgerald , Goldman Sachs Group , Securities Exchange Commission , Agios Pharmaceuticals , Agios Pharmaceuticals Stock Down , China Universal Asset Management Co , Investment Management , Headlands Technologies , Jpmorgan Chase Co , News Ratings For Agios Pharmaceuticals Daily , Zacks Research , Royal Bank , Nasdaq , Agios Pharmaceuticals Inc , Hedge Funds Weigh In On Agios Pharmaceuticals , Free Report , Agios Pharmaceutical , Pharmaceuticals Stock Down , Get Free Report , Director Jacqualyn , Exchange Commission , Universal Asset Management , Kantonalbank Zurich Cantonalbank , Agios Pharmaceuticals Daily ,